Drug Trial Radar · NCT07830238
SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
28
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Mar 2030
Study completion Mar 2030
Sponsor
- Lead sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- The First Hospital of Jilin University
- First posted
- Sep 21, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety and pharmacokinetic profile of SNC116 in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia
Conditions
- B-cell Acute Lymphoblastic Leukemia
Interventions
SNC116Drug
Subjects will receive SNC116 injection per different dose level
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Evaluation: The incidence rates, type and severity of all adverse eventsTime frame: with 3 months after infusion
- Safety Evaluation: DLTTime frame: with 28 days after infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First Hospital of Jilin University
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.